Galapagos en Gilead gaan definitieve overeenkomst aan over samenwerking om een first-in-class T-cel-engagerprogramma voor auto-immuunziekten verder te ontwikkelen
De nieuwe samenwerkingsstructuur levert aanzienlijk verbeterde financiële voorwaarden en flexibilite...
Publisher
Belgium
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
De nieuwe samenwerkingsstructuur levert aanzienlijk verbeterde financiële voorwaarden en flexibilite...
Source route
Continue on glpg.com
Leave the platform to read the original full article on the publisher site.
Source: Galapagos
Scope: Industry
Related coverage
More related coverage
BioInvent International AB publishes Annual Report 2025
Sobi publishes Annual and Sustainability Report for 2025
Swedish Orphan Biovitrum AB (publ) (Sobi®) today published its Annual and Sustainability report for...
Our R&D Approach
Powered by innovation, our R&D teams are driven to generate advances in drug discovery, out-innovate...
Research Funding Programs
Gilead funds external-sponsored research in virology, oncology & inflammation, a Research Scholars P...